期刊
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
卷 19, 期 1, 页码 22-27出版社
SAGE PUBLICATIONS INC
DOI: 10.2310/7750.2014.13151
关键词
-
类别
资金
- AbbVie
- Novartis
- Actelion
- Amgen
- Astellas
- Bio-K
- Celgene
- Galderma
- Janssen
- LEO Pharma
- Merck/Schering
- Pfizer
- Roche
- Valeant
- Abbott
- Centocor
- Isotechnika
- Lilly
- Merck
- Ortho Biotech
- Wyeth
- Eli Lilly
Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. Results: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). Conclusion: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据